Selected article for: "acute sars cov infection and lung injury"
Author: Su, Li; Tu, Ye; Kong, De-pei; Chen, Da-gui; Zhang, Chen-xi; Zhang, Wan-nian; Zhuang, Chun-lin; Wang, Zhi-bin
Title: Drug repurposing of anti-infective clinical drugs: Discovery of two potential anti-cytokine storm agents
  • Cord-id: cyvgy3x6
  • Document date: 2020_8_23
    • ID: cyvgy3x6
    Snippet: Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2) has been widely spread in the world with a high mortality. Cytokine storm syndrome (CSS) and acute lung injury caused by SARS-CoV-2 infection severely threaten the patients. With the purpose to find effective and low-toxic drugs to mitigate CSS, entecavir and imipenem were identified to reduce TNF-α using a LPS-induced macrophage model from the anti-infective drug library. Entecavir and i
    Document: Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2) has been widely spread in the world with a high mortality. Cytokine storm syndrome (CSS) and acute lung injury caused by SARS-CoV-2 infection severely threaten the patients. With the purpose to find effective and low-toxic drugs to mitigate CSS, entecavir and imipenem were identified to reduce TNF-α using a LPS-induced macrophage model from the anti-infective drug library. Entecavir and imipenem efficiently suppressed the release of inflammatory cytokines by partly intervention of NF-κB activity. The acute lung injury was also alleviated and the survival time was prolonged in mice. In addition, entecavir and imipenem inhibited the release of TNF-α and IL-10 in human peripheral blood mononuclear cells (hPBMCs). Collectively, we proposed that entecavir and imipenem might be candidates for the treatment of CSS.

    Search related documents:
    Co phrase search for related documents
    • aberrant excessive and acute lung injury: 1
    • aberrant excessive and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8
    • aberrant excessive and acute respiratory distress syndrome: 1, 2, 3, 4, 5
    • aberrant excessive and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6
    • acute ards respiratory distress syndrome and lopinavir remdesivir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute ards respiratory distress syndrome and lopinavir remdesivir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory and lopinavir remdesivir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and lopinavir remdesivir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and lopinavir remdesivir ritonavir abidol: 1
    • acute respiratory and lopinavir remdesivir ritonavir abidol ribavirin: 1
    • acute respiratory distress syndrome and lopinavir remdesivir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • acute respiratory distress syndrome and lopinavir remdesivir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute respiratory syndrome coronavirus and lopinavir remdesivir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome coronavirus and lopinavir remdesivir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome coronavirus and lopinavir remdesivir ritonavir abidol: 1
    • acute respiratory syndrome coronavirus and lopinavir remdesivir ritonavir abidol ribavirin: 1